Metastatic Renal Cell Carcinoma (mRCC): Epidemiology Forecasting Intelligence

Report ID: CmaxInsight 239 | Number of pages: 70 | Publish Date: Jun 2019 | Publisher: CmaxInsight | Category: Lifesciences and Healthcare
Our final report will cover impact analysis of COVID-19 outbreak
New
CmaxInsight’s “Metastatic Renal Cell Carcinoma (mRCC)-Epidemiology Forecasting Intelligence” report provides a comprehensive analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology, providing the historical, current, and forecasted data for the United States, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan during the period from 2018-2028.

Our epidemiology services include:
• Incidence and prevalence
• Diagnosis rate, treatment rate and mortality patterns
• Epidemiology-based forecasting and disease trends
• Size of different patient segments in a disease area
• Population based: disease occurrence, co-morbidities and treatment patterns
• Geographic - Regional - Ethnic differences

Along with the epidemiological data, the report also includes:
• Disease overview, causes, symptoms, classification, risk factor, pathophysiology, diagnosis and treatment
• Patient treatment journey
• Treatment algorithm and guidelines
• Assesses the disease risk and burden
• Highlights the unmet needs
• Market driver and barrier
• Growth opportunities and market trend analysis

Methodology
• This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Epidemiology Forecast model analysis by a team of industry experts.
• To generate accurate patient population estimates, utilizes a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies.
• All of the sources used to generate the data and analysis have been identified in the report.

Note: Systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Interested in this report?
Get your sample now!
1. Report Introduction
2. Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Overview at a Glance
3.  Market Share Distribution of Metastatic Renal Cell Carcinoma (mRCC)
4. Disease Background and Overview: Metastatic Renal Cell Carcinoma (mRCC)
4.1. Introduction
4.2. Signs and Symptoms
4.3. Etiology
4.4. Risk Factors
4.5. Pathophysiology
4.6. Diagnostic Landscape
4.6.1. Diagnostic Practices
4.6.2. Diagnostic Criteria
4.6.3. Diagnostic Recommendations
4.7. Treatment Landscape
4.7.1. Current Treatment Practices
4.7.2. Treatment Algorithm
4.7.3. Treatment Recommendations
5. Metastatic Renal Cell Carcinoma (mRCC) Epidemiology
5.1. Key Findings
5.2. Assumptions & Rationale
5.3. 7MM Epidemiology
6. Epidemiology of Metastatic Renal Cell Carcinoma (mRCC) by Countries
7. United States
7.1. Assumptions and Rationale
7.2. Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)
7.3. Sub-Type Specific cases of Metastatic Renal Cell Carcinoma (mRCC)*
7.4. Sex- Specific Cases of Metastatic Renal Cell Carcinoma (mRCC)*
7.5. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC)
7.6. Treated Cases of Metastatic Renal Cell Carcinoma (mRCC)
8. EU5
8.1. Germany
8.1.1. Assumptions and Rationale
8.1.2. Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.1.3. Sub-Type Specific cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.1.4. Sex- Specific Cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.1.5. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.1.6. Treated Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.2. France
8.2.1. Assumptions and Rationale
8.2.2. Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.2.3. Sub-Type Specific cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.2.4. Sex- Specific Cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.2.5. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.2.6. Treated Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.3. United Kingdom
8.3.1. Assumptions and Rationale
8.3.2. Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.3.3. Sub-Type Specific cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.3.4. Sex- Specific Cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.3.5. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.3.6. Treated Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.4. Spain
8.4.1. Assumptions and Rationale
8.4.2. Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.4.3. Sub-Type Specific cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.4.4. Sex- Specific Cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.4.5. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.4.6. Treated Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.5. Italy
8.5.1. Assumptions and Rationale
8.5.2. Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.5.3. Sub-Type Specific cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.5.4. Sex- Specific Cases of Metastatic Renal Cell Carcinoma (mRCC)*
8.5.5. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC)
8.5.6. Treated Cases of Metastatic Renal Cell Carcinoma (mRCC)
9. Japan
9.1. Assumptions and Rationale
9.2. Prevalent/Incident Cases of Metastatic Renal Cell Carcinoma (mRCC)
9.3. Sub-Type Specific cases of Metastatic Renal Cell Carcinoma (mRCC)*
9.4. Sex- Specific Cases of Metastatic Renal Cell Carcinoma (mRCC)*
9.5. Diagnosed Cases of Metastatic Renal Cell Carcinoma (mRCC)
9.6. Treated Cases of Metastatic Renal Cell Carcinoma (mRCC)
10. Unmet Needs
Appendix
Report Methodology
Sources Used
Disclaimer
About CmaxInsight
*Indication Specific

Note: Certain sections of the table of contents would vary according to the availability of information.
Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM
Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States
Table 4: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States*
Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States*
Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States
Table 7: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States
Table 8: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany
Table 9: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany*
Table 10: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany*
Table 11: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany
Table 12: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany
Table 13: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France
Table 14: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France*
Table 15: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France*
Table 16: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France
Table 17: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France
Table 18: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy
Table 19: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy*
Table 20: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy*
Table 21: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy
Table 22: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy
Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain
Table 24: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain*
Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain*
Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain
Table 27: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain
Table 28: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK
Table 29: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK*
Table 30: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK*
Table 31: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK
Table 32: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK
Table 33: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan
Table 34: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan*
Table 35: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan*
Table 36: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan
Table 37: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan

*Indication Specific
Figure 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States
Figure 4: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States*
Figure 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States*
Figure 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States
Figure 7: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States
Figure 8: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany
Figure 9: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany*
Figure 10: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany*
Figure 11: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany
Figure 12: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany
Figure 13: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France
Figure 14: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France*
Figure 15: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France*
Figure 16: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France
Figure 17: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United France
Figure 18: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy
Figure 19: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy*
Figure 20: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy*
Figure 21: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy
Figure 22: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy
Figure 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain
Figure 24: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain*
Figure 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain*
Figure 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain
Figure 27: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain
Figure 28: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK
Figure 29: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK*
Figure 30: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK*
Figure 31: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK
Figure 32: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK
Figure 33: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan
Figure 34: Sub-Type Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan*
Figure 35: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan*
Figure 36: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan
Figure 37: Treated Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan

*Indication Specific
This free Sample Report is purely a representation of our full report, for evaluating the market scope/data and make informed purchase decisions.